PharmTao, Santa Clara, CA, USA.
Methods Mol Biol. 2022;2547:141-163. doi: 10.1007/978-1-0716-2573-6_6.
The enormous heterogeneity of cancer systems has made it very challenging to overcome drug resistance and adverse reactions to achieve personalized therapies. Recent developments in systems biology, especially the perception of cancer as the complex adaptive system (CAS), may help meet the challenges by deciphering the interactions at various levels from the molecular, cellular, tissue-organ, to the whole organism. The ubiquitous Yin-Yang interactions among the coevolving components, including the genes and proteins, decide their spatiotemporal features at various stages from cancer initiation to metastasis. The Yin-Yang imbalances across different systems levels, from genetic mutations to tumor cells adaptation, have been related to the intra- and inter-tumoral heterogeneity in the micro- and macro-environments. At the molecular and cellular levels, dysfunctional Yin-Yang dynamics in the cytokine networks, mitochondrial activities, redox systems, apoptosis, and metabolism can contribute to tumor cell growth and escape of immune surveillance. Up to the organism and system levels, the Yin-Yang imbalances in the cancer microenvironments can lead to different phenotypes from breast cancer to leukemia. These factors may be considered the systems-based biomarkers and treatment targets. The features of adaptation and nonlinearity in Yin-Yang dynamical interactions should be addressed by individualized drug combinations, dosages, intensities, timing, and frequencies at different cancer stages. The comprehensive "Yin-Yang dynamics" framework would enable powerful approaches for personalized and systems medicine strategies.
癌症系统的巨大异质性使得克服药物耐药性和不良反应以实现个性化治疗极具挑战性。系统生物学的最新发展,特别是将癌症视为复杂适应系统(CAS)的认识,可能有助于通过破译从分子、细胞、组织器官到整个生物体各个层面的相互作用来应对这些挑战。共同进化的基因和蛋白质等组成部分之间无处不在的阴阳相互作用决定了它们在癌症发生到转移的各个阶段的时空特征。不同系统水平上的阴阳失衡,从基因突变到肿瘤细胞适应,与微环境和宏环境中的肿瘤内和肿瘤间异质性有关。在分子和细胞水平上,细胞因子网络、线粒体活性、氧化还原系统、细胞凋亡和代谢中的功能失调的阴阳动力学可导致肿瘤细胞生长和免疫监视逃逸。在个体和系统水平上,癌症微环境中的阴阳失衡可导致从乳腺癌到白血病的不同表型。这些因素可能被认为是基于系统的生物标志物和治疗靶点。应该通过个体化药物组合、剂量、强度、时间和频率在不同癌症阶段来解决阴阳动态相互作用中的适应和非线性特征。全面的“阴阳动力学”框架将为个性化和系统医学策略提供强大的方法。